Maxamine histamine dihydrochloride: Phase III

MAXM presented previously reported Phase III data showing that Maxamine plus low doses of interleukin-2 (IL-2) improved survival compared to the same doses of IL-2 alone (see BioCentury, May 8). The combination led to 25 percent survival at 2 years compared to 17 percent with IL-2 alone, and the combination produced an overall response in 38 percent of patients compared to 28 percent with IL-2 alone. ...